Exicure, Inc. (NASDAQ:XCUR – Get Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 164,900 shares, a decline of 39.9% from the May 31st total of 274,300 shares. Based on an average daily volume of 299,100 shares, the days-to-cover ratio is currently 0.6 days. Approximately 3.7% of the shares of the company are short sold.
Exicure Stock Performance
Shares of NASDAQ XCUR opened at $0.32 on Friday. The company has a market capitalization of $2.77 million, a PE ratio of -0.21 and a beta of 1.28. The company’s fifty day moving average price is $0.43 and its 200 day moving average price is $0.55. Exicure has a 1 year low of $0.30 and a 1 year high of $1.50.
Exicure (NASDAQ:XCUR – Get Free Report) last posted its earnings results on Thursday, May 16th. The company reported ($0.61) EPS for the quarter.
About Exicure
Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.
See Also
- Five stocks we like better than Exicure
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- How to Invest in Blue Chip Stocks
- MarketBeat Week in Review – 6/24 – 6/28
- High Flyers: 3 Natural Gas Stocks for March 2022
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
